Skip to main content

Table 1 Baseline patient characteristics

From: Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs

Patient characteristics (n = 41)
Age, years 53.3 (11.3)
Female gender, N (%) 24 (58.5)
Disease duration, years 10 (9)
Smoking, N (%)
 Current smoker 5 (12.2)
 Ex-smoker 13 (31.7)
 Never smoker 23 (56.1)
Remission duration, months 16.7 (14.4)
DAS-28 ESR, units 1.62 (0.68)
ESR, mm/h 11.5 (9.5)
CRP, mg/dL 0.26 (0.51)
Positive RF, N (%) 26 (63.4)
Positive ACPA, N (%) 28 (68.3)
Methotrexate use, N (%) 27 (65.9)
Other csDMARD use, N (%) 2 (4.9)
Biological DMARD use, N (%)
 Adalimumab 14 (34.1)
 Tocilizumab 10 (24.4)
 Etanercept 9 (22.0)
 Certolizumab pegol 6 (14.6)
 Golimumab 2 (4.9)
 Patients with flare, N (%) 20 (48.8)
  1. Values are means (SD) if not stated otherwise
  2. ACPA anti-citrullinated peptide antibodies, CRP C-reactive protein, DAS-28 Disease Activity Score 28 joints, DMARD disease-modifying anti-rheumatic drugs, cs conventional synthetic, ESR erythrocyte sedimentation rate